Dr. Czaplewski is Chief Scientific Officer for Persica Pharmaceuticals Limited and a Director of Chemical Biology Ventures, providing life & chemical sciences consultancy services. Previously Dr. Czaplewski served as an R&D executive for Biota, Prolysis, and British Biotech Pharmaceuticals.
Scientific career highlights include the creation of an engineered cytokine, discovery of the potential for minimal lentiviral vectors in antigen presentation, and demonstrating ability to create and lead structure-informed screening, hit & lead optimization programs against GTPases (FtsZ) and ATPases (GyrB/ParE) leading to compounds with class leading in vivo antibacterial efficacy, in addition to a prolific patent and publication record. Dr. Czaplewski has hired outstanding teams, and raised millions of pounds from UK, Europe, USA and Japan.
Dr. Czaplewski serves on many boards and advisory boards including the Novo Repair Impact Scientific Selection Board, CARB-X Advisory Board Funding Panel member, WHO Antibiotic Advisory Panel, , Pew Trust Advisory Board, and the Antibiotic Research UK SAB.
Dr. Czaplewski earned his PhD in Molecular Genetics from the University of Glasgow and a First Class B.Sc in Biological Sciences from the University of East Anglia. He is an elected fellow of the Royal Society of Chemistry.